NRX Archives - Page 5 of 6 - NRx Pharmaceuticals

Mar. 28, 2022

NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022

NRx Pharmaceuticals, Inc. announced that management will report year end 2021 financial results prior to the market open on March 31, 2022. The company will host a conference call and webcast on March 31, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period.

Mar. 18, 2022

NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer

NRx Pharmaceuticals, Inc. announced today that the company’s Board of Directors appointed Ira Strassberg as Chief Financial Officer and Treasurer effective March 15, 2022.

Mar. 8, 2022

NRx Pharmaceuticals Announces Leadership Transition

NRx Pharmaceuticals, a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer effective immediately. The Board of Directors appointed Robert Besthof, Head of Operations and Chief Commercial Officer, as Interim CEO.

Recent Publication regarding the use of Zyesami®

Source – https://spotonflorida.com/north-central-florida/3555710/lauds-mothers-covid-recovery-after-experimental.html?fbclid=IwAR31nFkp71HPsff_C9YKR84H9KzNpWavAbjlQWJ8FRrlQI8zWNnmnGo0Bb8

Feb. 23, 2022

Potential For First In Bipolar Depression Suicidal Ideation Treatment, ZYESAMI Has Potential For Treatment of Severe Covid-19 Patients

NRx Pharmaceuticals is a great speculative biotech to look into. While there are many types of treatments and vaccines for Covid-19, NRX-101 gives the company a chance to get into the bipolar depression space as well. Even then, there is a possible expansion opportunity for ZYESAMI beyond Covid-19.

Feb. 11, 2022

NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

NRx Pharmaceuticals reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, on the future of the BriLife™ Covid-19 Investigational Vaccine.

Feb. 2, 2022

NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules

NRx Pharmaceuticals today announced that it has closed its previously announced private placement priced at a premium to market under Nasdaq rules of 7,824,727 shares of its common stock and unregistered preferred investment options to purchase up to an aggregate of 7,824,727 shares of common stock.

Jan. 31, 2022

NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules

NRx Pharmaceuticals today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to market under Nasdaq rules.

Jan. 27, 2022

NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of neutralizing antibody against the Omicron variant of the SARS-CoV-2 virus.

Cookie	Duration	Description
_wpfuuid	11 years	This cookie is used by the WPForms WordPress plugin. The cookie is used to allows the paid version of the plugin to connect entries by the same user and is used for some additional features like the Form Abandonment addon.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
nlbi_1816097	session	A load balancing cookie set to ensure requests by a client are sent to the same origin server.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
visid_incap_1816097	1 year	SiteLock sets this cookie to provide cloud-based website security services.

Cookie	Duration	Description
_jsuid	1 year	This cookie contains random number which is generated when a visitor visits the website for the first time. This cookie is used to identify the new visitors to the website.
cluid	1 year	This cookie is used for websites which is having multiple domains to identify the same visitor across multiple domains.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
mo_has_visited	11 years	This cookie is used for setting an unique ID for the visitor which helps to get the accurate number of specific visitor on the website.
mo_is_new	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.
mo_page_views_counter	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.

Cookie	Duration	Description
c	6 months 2 days	This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services.
uuid	1 year 27 days	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
incap_ses_1371_1816097	session	No description
unpoco_101344884	1 day	No description